IFITM2 Antibody (YA8830)(PBS only)

Cat. No.: HY-P89146A: Data Sheet User Guide for Antibodies
FAQs
Technical Support

IFITM2 Antibody (YA8830) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to IFITM2.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

사이즈		재고
50 μL		견적 받기
100 μL		견적 받기

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
제품 설명

제품 설명

IFITM2 Antibody (YA8830) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to IFITM2.

Host

Mouse

분자량

Predicted band size: 14.5 kDa

Species Reactivity

Human

SwissProt ID

Q01629

Immunogen

Full length human recombinant protein of human IFITM2 produced in E.coli.

Application &
Dilution Ratio

Application	Dilution Ratio
IHC-P IHC-P: Immunohistochemistry-Paraffin	1:500-800

Purity	Affinity purified	Conjugation	Non-conjugated
Isotype	IgG2a

Appearance

Liquid

Formulation

Supplied in PBS, pH 7.4.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

선적

Shipping with blue ice.

Background

Function：IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol (PubMed:26354436, PubMed:33563656). Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1), hepatitis C virus (HCV) and vesicular stomatitis virus (VSV) (PubMed:26354436, PubMed:33239446, PubMed:33270927, PubMed:33563656). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS-CoV and SARS-CoV-2 S protein-mediated viral entry and VSV G protein-mediated viral entry (PubMed:33563656). Induces cell cycle arrest and mediates apoptosis by caspase activation and in p53-independent manner. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation (PubMed:26354436). IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome (PubMed:26354436)

Subcellular Localization：Cell membrane,Lysosome membrane,Late endosome membrane

Expression：Induction: By IFN-alpha, IFNB1/IFN-beta and IFNG/IFN-gamma. Down-regulated by p53/TP53

Isoforms & Post-Translational Modification：Q01629: 132 amino acids, molecular weight 14632 Da.

Subunit：Interacts with CD81

Synonyms

1-8D; DSPA2c

각종 서류

User Guide for Antibodies (1077 KB)